Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries

Table 2 Cost parameters, by country

	Germany [36]	Switzerland	Greece	Netherlands	Poland	Serbia	UK (NHS England)
Outpatient costs (index, DE = 100) [OECD] [35]	100	180	88	126	44	43	123
Screening costs per app (screened patient)	47.54 €	47.54 €	*41.84 €	47.54 €	*20.92 €	*20.44 €	47.54 €
Validation cost	297.50 €	297.50 €	261.80 €	297.50 €	130.90 €	127.93 €	297.50 €
VKA (%) [42]	35%	35%	35%	35%	35%	35%	35%
OAC: Cost per day
VKA cost/d	0.20 €	0.33 €	0.12 €	0.12 €	0.05 €	0.03 €	0.04 €
NOAC cost/d	3.00 €	3.39 €	2.49 €	3.43 €	2.76 €	3.51 €	2.68 €
Average inpatient stroke costs € per stay	4007 €	11,344 €	2864 €	5328 €	2050 €	803 €	4973 €
Inpatient costs/stroke (index, DE = 100)	100	283	71	133	49	20	124
Bleeding costs	Germany: 50 € (minor)/2025 € (major); country specific prices proportional to outpatient cost index

Outpatient cost index: health price index, OECD 2014; levels normalized to German level (Germany = 100)
Screening costs: German costs (source Preventicus price list 06(2020) applied to Western European countries. For Greece, Serbia and Poland prices were adjusted proportionally to the OECD health price inces
OAC medication: government/health authority catalogues (Greece, Serbia, Netherlands, UK), retail prices (Poland, Switzerland, Germany); Inpatient cost index: rough estimate from DRG costs, stroke subsections (see Supplement, Tables 3 and 4)
*Adjusted to country-specific cost levels

ISSN: 2191-1991